UBS says Evolent Health (EVH) on Monday issued a press release that is “incrementally positive.” The company issued a confirmation that oncology cost trends remain below expectations, a new debt commitment from Ares, a reiteration of its adjusted EBITDA guidance for Q2 and 2025, new debt financing to address 2025 convertibles, and also flagged a pickup in late-stage pipeline activity, the analyst tells investors in a research note. UBS believes that despite a solid Q1, Evolent shares are down 9% since April, largely on concerns that oncology cost trends remain elevated due.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- GMS jumps after report of competing suitors, Couchbase gets bought: Morning Buzz
- Evolent Health Amends Credit Agreement for Flexibility
- Evolent Health backs Q2 adjusted EBITDA view $33M-$40M
- Evolent Health Restructures Board Committees in June 2025
- Evolent Health Reaffirms 2025 Revenue and EBITDA Guidance
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue